Background
==========

Studies using genetically modified mouse models have contributed a great deal to our understanding of molecular mechanisms that govern critical embryonic development processes, such as neural tube closure. Among the over 200 existing mouse models for neural tube defects (NTDs), several harbor mutations in genes encoding transcriptional activators or co-activators, such as *Cited2*, *Crebbp*, *p300*, *Tfap2α, Carm1*and *Cart1*\[[@B1]-[@B9]\].

CREB binding protein (CREBBP; CBP) was originally identified as a protein that binds to the phosphorylated form of the CREB transcription factor and increases the expression of genes containing CRE elements. It is closely related to the adenovirus E1A-associated protein p300. CBP and p300 are functionally redundant histone deacetylases essential for proliferation and embryonic development \[[@B5],[@B8],[@B10]\]. Both *Crebbp*and *p300*genes are expressed at high level in the neural folds at embryonic day E8.5 in mice \[[@B3]\]. Homozygous deletions of either the *Crebbp*or *p300*genes in mice results in lethality on E9\~11, with subsequent defects in neurulation, cell proliferation and cardiac development \[[@B5],[@B8]\].

The methylation of the Crebbp/p300 complex is catalyzed by co-activator-associated arginine methyltransferase (CARM1). This process disables the recruitment of cAMP response element binding protein (CREB). Thus, CARM1 functions as a co-repressor in the cAMP signaling pathway, via its methyltransferase activity \[[@B11]\]. In addition to its enzymatic function, CARM1 is also required for NF-kappaB-dependent gene expression as a transcriptional cofactor \[[@B12]\]. *Carm1*gene expression was observed in the fore- and hindbrain, neural folds, somites and posterior lateral plates of E8.25 mouse embryos, and later on in development (E8.75) expression became prominent in the neural tube and somites \[[@B13]\].

CITED2 is a nuclear co-activator that binds to CBP/p300. Disruption of the *Cited2*gene in mice is embryonic lethal, with the mice dying secondary to significant defects in the development of the neural tube and the heart \[[@B2],[@B6],[@B14],[@B15]\]. The interaction of CBP and p300 with *Cited2*is required for activation of important transcriptional factors such as AP-2α \[[@B1],[@B16]\]. Mice carrying homozygous disruptions of the gene coding for the protein AP-2 α (*Tfap2*α) die at term as a result of severe developmental abnormalities. The earliest defect observed was a complete failure of neural tube closure in the cranial region, and it has been suggested in a chimera model study that there is an independent requirement for AP-2 α in the formation of the neural tube \[[@B17]-[@B19]\].

CART1 is a paired-class homeobox-containing transcription factor regulated by CBP/p300 acetylation of a highly conserved lysine residue that increases the interaction between CBP/p300 and CART1, ultimately enhancing its transcriptional activation \[[@B20]\]. The *Cart1*gene is expressed in chondrocytes \[[@B21],[@B22]\], and appears to be required for embryonic forebrain mesenchymal survival. The absence of CART1 disrupts cranial neural tube morphogenesis by blocking the initiation of closure in the midbrain region. Homozygous *Cart1*mutant mice are born alive with neural tube closure defects including acrania and meroanencephaly, but die soon after birth \[[@B9]\]. The *Cart1*knockout mouse is among several NTD mouse models that can be rescued by maternal supplementation with folic acid \[[@B23]\]. The gene encoding human CART1 is *ALX1*(ALX homobox 1). In summary, CBP, p300, CARM1, TFAP2α, CITED2 and CART1 are transcriptional activator/co-activators that contributes to the ontogeny of the neural tube in mammalian systems. Whether gene homologues are associated with human NTDs remains unknown. Three single nucleotide polymorphisms (SNP) in the un-translated region of *CITED2*gene were studied in a group of patients with spina bifida and controls, modest associations were observed but results were imprecise owing to small sample size \[[@B14]\]. Mutations in the human *CBP*gene have been identified as being responsible for the Rubinstein-Taybi syndrome (RTS), which has a defined craniofacial phenotype \[[@B4]\]. The purpose of this study is to evaluate the potential association between variations among human *CITED2*, *CREBBP*, *EP300*, *TFAP2A*, *CARM1*and *ALX1*genes and the risk for spina bifida.

Methods
=======

Study Population
----------------

Data and biological samples were obtained from a case-control study conducted by the California Birth Defects Monitoring Program (CBDMP). The CBDMP is an active, population-based surveillance system for collecting information on infants and fetuses with structural congenital malformations, which has been described elsewhere \[[@B24]\]. Included were 297 singleton infants with spina bifida (cases) and 300 non-malformed infants (controls). Both cases and controls were randomly selected from the samples with bloodspots available. Cases were selected from California Birth Defect Registry 1990-1999; non-malformed controls were selected from Vital Statistics matching the birth years with the selected cases. Case and control infants were linked to their newborn screening bloodspots. All samples were obtained with approval from the State of California Health and Welfare Agency Committee for the Protection of Human Subjects.

Candidate genes and SNPs
------------------------

The 6 candidate genes and SNPs genotyped are listed in Table [1](#T1){ref-type="table"}. Tagging SNPs were selected for each candidate gene using the SNPbrowser™ Software (ABI, Foster City, CA) based on data from the four HapMap populations (CEU, YRI, JPT and CHB) \[[@B25]\]. All validated tagging SNPs with pairwise r^2^\> = 0.8 with a minor allele frequency (MAF) no less than 5% were included for genotyping. Also included for study were all non-synonymous coding SNPs in these genes. Based on these criteria, 37 SNPs were genotyped.

###### 

Characteristics of all genotyped SNPs

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene\            Marker           Chromosome   Chromosome position   RefSNP alleles   Call Rate\   MAF\*\           HWE P\       MAF\        HWE\*\* P\         MAF\         HWE P\
  (Alias)                                                                               (%)          (All subjects)   (controls)   (White)     (White controls)   (Hispanic)   (Hispanic controls)
  ---------------- ---------------- ------------ --------------------- ---------------- ------------ ---------------- ------------ ----------- ------------------ ------------ ---------------------
  *ALX1 (CART1)*   rs11608773       12           84229006              A/G              100.0        0.229            0.435        0.274       0.478              0.217        0.391

                                                                                                                                                                               

                   rs4761130        12           84226396              C/T              99.8         0.421            0.286        0.358       0.154              0.401        0.465

                                                                                                                                                                               

                   rs7295242        12           84222948              A/G              100.0        0.161            0.781        0.074       0.557              0.159        0.358

                                                                                                                                                                               

  *CARM1*          rs11667234       19           10880581              A/C              99.8         0.021            0.010        0.039       0.071              0.016        0.934

                                                                                                                                                                               

                   rs11670365       19           10865833              C/T              100.0        0.056            0.918        0.084       0.754              0.045        0.702

                                                                                                                                                                               

                   rs1529711        19           10884434              A/G              99.7         0.097            0.492        0.161       0.932              0.081        0.519

                                                                                                                                                                               

                   rs1541596        19           10848013              A/G              99.5         0.475            0.326        0.497       0.969              0.408        0.957

                                                                                                                                                                               

                   rs17616105       19           10883159              C/T              100.0        0.189            0.732        0.235       0.365              0.152        0.072

                                                                                                                                                                               

                   rs7254708        19           10863579              A/G              100.0        0.071            0.043        0.123       0.116              0.059        0.441

                                                                                                                                                                               

  *CITED2*         rs1131431        6            139735527             A/G              100.0        0.153            0.273        0.200       0.624              0.121        0.948

                                                                                                                                                                               

                   **rs7775752**    6            139737486             **A/G**          **45.1**     **0.007**        **0.957**    **0.009**   **0.913**          **0.006**    **1.000**

                                                                                                                                                                               

  *CREBBP (CBP)*   rs11076783       16           3722706               C/T              100.0        0.154            0.638        0.116       0.142              0.139        0.802

                                                                                                                                                                               

                   **rs11076785**   16           3730187               **G/T**          **46.6**     **0.457**        **0.638**    **0.401**   **0.185**          **0.457**    **0.463**

                                                                                                                                                                               

                   rs11076786       16           3751597               C/T              100.0        **0.075**        **0.008**    0.077       0.441              0.046        0.637

                                                                                                                                                                               

                   rs129986         16           3744242               C/T              100.0        0.023            0.530        0.032       0.590              0.020        0.735

                                                                                                                                                                               

                   rs130003         16           3768173               A/G              99.8         0.015            0.792        0.032       0.711              0.010        0.967

                                                                                                                                                                               

                   rs130008         16           3721953               C/G              99.8         0.011            0.838        0.032       0.752              0.001        1.000

                                                                                                                                                                               

                   rs17136507       16           3740546               C/T              100.0        0.178            0.536        0.110       0.229              0.227        0.449

                                                                                                                                                                               

                   rs886528         16           3751557               C/T              99.7         0.383            0.590        0.390       0.986              0.368        0.839

                                                                                                                                                                               

                   rs9392           16           3715170               A/G              99.8         0.189            0.566        0.223       0.625              0.138        0.700

                                                                                                                                                                               

  *EP300 (P300)*   rs17002284       22           39826792              A/G              100.0        0.265            0.220        0.313       0.745              0.217        0.522

                                                                                                                                                                               

                   rs17433014       22           39829768              A/G              99.8         0.018            0.769        0.029       0.793              0.019        0.834

                                                                                                                                                                               

                   rs2230111        22           39851949              A/G              99.8         0.002            0.977        0.006       0.959              1.000        1.000

                                                                                                                                                                               

                   rs4820428        22           39867535              A/G              100.0        **0.446**        **0.006**    0.329       0.822              0.419        0.667

                                                                                                                                                                               

                   rs4820429        22           39868057              C/G              100.0        0.159            0.382        0.258       0.040              0.124        0.471

                                                                                                                                                                               

                   rs4822006        22           39849308              C/T              100.0        0.247            0.844        0.355       0.587              0.185        0.740

                                                                                                                                                                               

                   rs5758246        22           39871792              A/G              100.0        0.030            0.635        1.000       1.000              0.012        0.934

                                                                                                                                                                               

                   rs9611502        22           39861182              C/T              100.0        0.014            0.838        0.019       0.918              0.013        0.867

                                                                                                                                                                               

  *TFAP2A (AP2)*   rs10456013       6            10506548              G/T              100.0        0.032            0.592        0.048       0.670              0.026        0.735

                                                                                                                                                                               

                   rs1621700        6            10528084              A/G              99.7         0.288            0.671        0.252       0.081              0.357        0.773

                                                                                                                                                                               

                   rs303050         6            10511169              C/T              100.0        0.257            0.061        0.165       0.259              0.262        0.267

                                                                                                                                                                               

                   rs303055         6            10527462              C/T              100.0        0.353            0.150        0.435       0.569              0.335        0.025

                                                                                                                                                                               

                   rs303056         6            10528467              C/G              100.0        0.159            0.229        0.094       0.477              0.126        1.000

                                                                                                                                                                               

                   rs3798691        6            10519381              C/G              100.0        0.112            0.021        0.042       0.011              0.134        0.111

                                                                                                                                                                               

                   rs3798694        6            10516743              A/G              100.0        0.062            0.122        0.087       0.225              0.059        0.293

                                                                                                                                                                               

                   rs533558         6            10503558              A/G              100.0        0.441            0.848        0.361       0.955              0.481        0.858

                                                                                                                                                                               

                   rs537112         6            10503192              A/G              100.0        0.180            0.571        0.103       0.754              0.195        0.255
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*MAF: minor allele frequency; \*\*HWE: Hardy-Weinberg Disequilibrium

Genotyping Approach
-------------------

DNA was extracted from blood spots using the Gentra Puregene DNA Extraction Kit (Qiagen, Valencia, CA) following the standard protocol. Prior to genotyping, genomic DNA was amplified using a commercially available multiple displacement amplification (MDA) kit, GenomiPhi DNA Amplification kit (GE Healthcare, Piscataway, NJ). The whole genome amplification (WGA) product was then quantified using RNase P assay (AppliedBiosystems, Foster City, CA). 200 ng of WGA product was used for the SNPlex assay containing the 37 SNPs. All genotyping assays were performed blinded to subjects\' case or control status.

The SNPs selected for analyses were submitted to Applied Biosystems to create a unique SNPlex assay. The SNPlex™ genotyping system (Applied Biosystems, Foster City, CA) is based on a universal multiplexed oligonucleotide ligation assay (OLA)/PCR and drag chute mobility modifier technology. The resulting genotype data were analyzed using GeneMapper™ v4.0 (Applied Biosystems, Foster City, CA).

Analytic procedures
-------------------

Analyses were performed for the overall study group as well as for specific ethnic/race groups. Hispanic infants were further subdivided into those whose mothers were born in the United States, or native-born (Hisp-NB) and those whose mothers were not, or foreign-born (Hisp-FB), as it has been shown that these two groups are different with respect to ethnic composition and social economic status \[[@B26],[@B27]\]. Departure from Hardy-Weinberg Equilibrium (HWE) was assessed by Chi-square analysis in each subgroup using data from controls only. Odds ratios (OR) for SNP genotypes were calculated using logistic regression analyses. Since the mode of inheritance is unknown, potential associations with spina bifida risk were evaluated assuming dominant, recessive and additive models for each SNP. Chi-square tests were used to assess the significance of dominant and recessive models. Cochran-Armitage trend tests were used to assess the significance of additive models. If numbers were less than 5, Fisher\'s exact test and Exact Armitage trend test were applied. Analyses were performed using SVS v7.1.1 (GoldenHelix, Bozeman, MT) software. The false discovery rate (FDR) \[[@B28]\] was used to account for multiple testing (data not shown). Haplotype blocks were constructed using HaploView 4.2 <http://www.broadinstitute.org/haploview/haploview> in each race/ethnicity group with pair-wise D\'≥0.85. Haplotype frequencies were estimated based on the Maximum Expectation (EM) algorithm. Association of each haplotype was evaluated by calculating ORs and 95% confidence intervals against all other haplotypes. Estimated risks were considered statistically precise if 95% confidential interval of OR does not include 1.00.

Results and Discussion
======================

Demographic characteristics of the cases and controls are listed in Table [2](#T2){ref-type="table"}. Cases and controls were similar with respect to maternal age, parity, and plurality but expectedly differed with respect to race/ethnicity and maternal educational attainment. That is, the data revealed greater frequencies of Hispanics (primarily foreign born) and women with low educational level (less than high school) in the spina bifida case group.

###### 

Demographic distribution of malformed cases and non-malformed controls, California 1990-1999

  Variable                           Spina Bifida   
  ---------------------------------- -------------- ------------
  Maternal Race/Ethnicity                           
   White, non-Hispanic               59 (19.9)      96 (32.0)
   Hispanic, Native Born             33 (11.1)      33 (11.0)
   Hispanic, Foreign Born            166 (55.9)     115 (38.3)
   Black                             17 (5.7)       20 (6.7)
   Asian                             9 (3.0)        25 (8.3)
   Other                             9 (3.0)        11 (3.7)
  Maternal age at delivery (years)                  
   13-24                             128 (43.1)     123 (41.0)
   25-29                             80 (26.9)      71 (23.7)
   30-34                             47 (15.8)      64 (21.3)
   35-55                             39 (13.1)      42 (14.0)
  Maternal education                                
   Less than high school             158 (53.2)     110 (36.7)
   High School                       65 (21.9)      81 (27.0)
   Greater than High school          71 (23.9)      109 (36.3)
  Parity                                            
   0                                 120 (40.4)     114 (38.0)
   1                                 88 (29.6)      101 (33.7)
   ≥ 2                               86 (29.0)      84 (28.0)
  Plurality                                         
   Singleton                         287 (96.6)     293 (97.7)
   Multiple births                   8 (2.7)        7 (2.3)
  Infant Sex                                        
   Male                              146 (49.2)     149 (49.7)
   Female                            151 (50.8)     151 (50.3)

^1^Percentages may not equal 100 owing to missing data or rounding.

Genotyping of 37 SNPs was performed using a custom-made Applied Biosystems SNPlex panel. Due to low call rates, two SNPs, rs7775752 (45.1%) and rs11076785 (46.6%), were excluded from analysis. Departure from HWE in the controls (*p*\< 0.01) was observed in rs11076786 and rs4820428 when analyzing the whole dataset. This deviation was eliminated when stratified by race/ethnicity (Table [1](#T1){ref-type="table"}). Several SNPs and haplotypes containing these SNPs showed modest associations with spina bifida risk (p ≤ 0.05, Table [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}). These associations are summarized below for each gene. The results, however, are largely indicative of no or very limited associations, particularly after correction for multiple comparisons.

###### 

Allele associations (P \< 0.05) among subgroups

  ----------------------------------------------------------------------------------------------------------------------------------
  SNP          Gene             Ethnicity      refSNP alleles   Minor Allele   Ratio Counts\      P value   Odds Ratio   95% CI
                                                                               (Case, Control)                           
  ------------ ---------------- -------------- ---------------- -------------- ------------------ --------- ------------ -----------
  rs129986     *CREBBP (CBP)*   white          C/T              T              118:0, 182:10      0.008\*   n/a          n/a

                                                                                                                         

  rs17616105   *CARM1*          white          C/T              C              101:17, 136:56     0.003     2.45         1.34-4.46

                                                                                                                         

  rs303056     *TFAP2A (AP2)*   white          C/G              C              16:102, 13:179     0.046     2.16         1.00-2.15

                                                                                                                         

  rs3798691    *TFAP2A (AP2)*   Hispanic       C/G              C              65:333, 29:267     0.013     1.80         1.13-2.87

                                                                                                                         

                                Hispanic-FB    C/G              C              52:280, 22:208     0.036     1.76         1.03-2.98

                                                                                                                         

  rs533558     *TFAP2A (AP2)*   Hispanic-NB    A/G              G              36:30, 24:42       0.036     2.10         1.05-4.22

                                                                                                                         

  rs4820428    *EP300 (P300)*   All subjects   A/G              G              276:240, 229:259   0.038     1.30         1.01-1.67
  ----------------------------------------------------------------------------------------------------------------------------------

###### 

Genotype associations (P \< 0.05) among subgroups under different modes of inheritance

  ----------------------------------------------------------------------------------------------------------------------------------
  Marker       Gene       Ethnicity      *P*value   Mode of Inheritance         Odds Ratio\                       95% CI
                                                                                \[(ratio count (case, control))   
  ------------ ---------- -------------- ---------- --------------------------- --------------------------------- ------------------
  rs17002284   *EP300*    All subjects   0.012      Recessive                   **0.43 (13, 29; 284, 271)**       **0.22 - 0.84**

                                                                                                                  

  rs4820428    *EP300*    All subjects   0.011      Additive \[(Dd) vs (dd)\]   **1.46 (132, 122; 87, 117)**      **1.00 - 2.11**

                                                                                                                  

                                                     \[(DD) vs (Dd)\]           1.18 (78, 61; 132, 122)           0.78 - 1.79

                                                                                                                  

                          All subjects   0.012      Dominant                    **1.54 (210, 183; 87, 117)**      **1.10 - 2.17**

                                                                                                                  

  rs4820429    *EP300*    All subjects   0.046      Dominant                    **0.70 (75, 98; 222, 202)**       **0.49 - 0.99**

                                                                                                                  

                          White          0.041      Dominant                    **0.50 (22, 52; 37, 44)**         **0.26 - 0.50**

                                                                                                                  

  rs1621700    *TFAP2A*   All subjects   0.041      Additive \[(Dd) vs (dd)\]   1.30 (131, 118; 138, 161)         0.92 - 1.81

                                                                                                                  

                                                     \[(DD) vs (Dd)\]           1.33 (28, 19; 131, 118)           0.70 - 2.50

                                                                                                                  

  rs3798691    *TFAP2A*   Hispanic       0.015      Additive \[(Dd) vs (dd)\]   **1.78 (48, 23; 143, 122)**       **1.04 - 3.19**

                                                                                                                  

                                                     \[(DD) vs (Dd)\]           1.40 (9, 3; 47, 22)               0.35 - 5.70

                                                                                                                  

                          Hispanic       0.022      Dominant                    **1.84 (56, 26; 143, 122)**       **1.13 - 3.25**

                                                                                                                  

                          Hispanic-FB    0.049      Dominant                    **1.82 (44, 19; 122, 92)**        **1.00 - 3.40**

                                                                                                                  

  rs533558     *TFAP2A*   Hispanic-NB    0.038      Additive \[(Dd) vs (dd)\]   3.00 (18, 14; 6, 14)              0.92 - 9.80

                                                                                                                  

                                                     \[(DD) vs (Dd)\]           1.40 (9, 5; 18, 14)               0.38 - 5.12

                                                                                                                  

                          Hispanic-NB    0.032      Dominant                    **3.32 (27, 19; 6, 14)**          **1.08 - 10.18**

                                                                                                                  

  rs17616105   *CARM1*    Hispanic       0.0        Recessive                   n/a (6, 0; 193, 148)              n/a

                                                                                                                  

                          White          0.004      Additive \[(Dd) vs (dd)\]   0.48 (15, 36; 43,50)              0.23 - 1.00

                                                                                                                  

                                                     \[(DD) vs (Dd)\]           0.24 (1,10; 15,36)                0.03 - 2.04

                                                                                                                  

                          White          0.010      Dominant                    **0.40 (16, 46; 43, 50)**         **0.40 - 0.20**

                                                                                                                  

  rs1131431    *CITED2*   White          0.027      Recessive                   **5.32 (6, 2; 53, 94)**           **1.04 - 27.30**

                                                                                                                  

  rs129986     *CREBBP*   All subjects   0.005      Additive \[(Dd) vs (dd)\]   **0.27 (6, 21; 291, 279)**        **0.11 - 0.69**

                                                                                                                  

                                                     \[(DD) vs (Dd)\]           n/a (0, 0; 6, 21)                 n/a

                                                                                                                  

                          All subjects   0.003      Dominant                    **0.27 (6, 21; 291, 279)**        **0.11 - 0.69**

                                                                                                                  

                          White          0.014      Additive \[(Dd) vs (dd)\]   n/a (0, 10; 59, 86)               n/a

                                                                                                                  

                                                     \[(DD) vs (Dd)\]           n/a (0, 0; 0, 10)                 n/a

                                                                                                                  

                          White          0.010      Dominant                    n/a (0, 10; 59, 86)               n/a
  ----------------------------------------------------------------------------------------------------------------------------------

CITED2
------

Only one of the two SNPs genotyped was fully analyzed. SNP rs1131431 showed a genotypic association (OR = 5.32, 95% CI: 1.04\~27.30) based on a recessive mode of inheritance, specifically in the White population. It is noteworthy that the confidence interval had a wide range, suggesting that the estimate may be imprecise due to the small number of White cases and controls with the variant. This SNP, however, was previously associated with a modest increase in risk for spina bifida and congenital heart defects \[[@B14]\].

EP300
-----

Among the 8 SNPs analyzed, the G allele of SNP rs4820428 was over-represented in spina bifida cases (OR = 1.30, 95% CI: 1.01\~1.67) in all subjects. Analyses showed that rs4820428 was associated with spina bifida risk under a dominant model (OR = 1.54 95%CI: 1.10\~2.17). The minor allele of rs4820429 (C) showed a reduced risk in the Whites (OR = 0.50, 95% CI: 0.26\~0.50) and in the whole dataset (OR = 0.70, 95% CI: 0.49\~0.99) under a dominant model. Minor allele of rs17002284 (G) also showed a reduced risk (OR = 0.43, 95%CI: 0.22\~0.84), but under a recessive model. These three SNPs were in linkage disequilibrium. Subsequent analysis showed that haplotype ACGG (rs17002284-rs4822006-rs4820428-rs4820429) accounted for 50.3% of all haplotypes in the Whites and was over-represented in the white cases (OR = 1.30, 95%CI: 1.01\~1.67). It is noteworthy that this high risk haplotype contains the high risk alleles for rs17002284 (A), rs4820428 (G) as well as rs4820429 (G) (Table [5](#T5){ref-type="table"}).

###### 

Haplotype associations (only significant associations are shown)

  Haplotype Block                                                                 Frequency   P Value      Odds Ratio (case, control)                95% CI
  ------------------------------------------------------------------------------- ----------- ------------ ----------------------------------------- ---------------
  *TFAP2A*-rs537112, rs533558, rs303050, rs3798694, and rs3798691 in Hispanic                                                                        
                                                                                                                                                     
  **AGCGC**                                                                       **0.133**   **0.0205**   **1.73 (63.0 : 335.0, 29.0 : 267.0)**     **1.08-2.77**
  GATGG                                                                           0.516       0.2019       0.82 (197.0 : 201.0, 161.0 : 135.0)       0.61-1.11
  GGTGG                                                                           0.201       0.8135       0.96 (78.9 : 319.1, 60.8 : 235.2)         0.66-1.39
  GGCAG                                                                           0.058       0.4974       1.26 (25.0 : 373.0, 15.0 : 281.0)         0.65-2.43
  AGCGG                                                                           0.041       0.3207       0.69 (13.9 : 384.1, 14.8 : 281.2)         0.33-1.45
  GGCGG                                                                           0.028       0.6568       0.81 (10.1 : 387.9, 9.2 : 286.8)          0.33-2.00
  AGTGG                                                                           0.021       0.9639       0.97 (8.1 : 389.9, 6.2 : 289.8)           0.34-2.79
                                                                                                                                                     
  *EP300*- rs17002284, rs4822006, rs4820428 and rs4820429 in non-Hispanic white                                                                      
                                                                                                                                                     
  **ACGG**                                                                        **0.503**   **0.0377**   **1.30 (276.0 : 240.0, 229.0 : 259.0)**   **1.01-1.67**
  GCAG                                                                            0.245       0.1665       0.82 (117.0 : 399.0, 129.0 : 359.0)       0.61-1.09
  ATAC                                                                            0.163       0.054        0.72 (73.0 : 443.0, 91.0 : 397.0)         0.51-1.00
  ATAG                                                                            0.072       0.8074       1.06 (38.0 : 478.0, 34.0 : 454.0)         0.66-1.72
  ACAG                                                                            0.015       0.2348       1.91 (10.0 : 506.0, 5.0 : 483.0)          0.65-5.63

TFAP2
-----

Among the 9 SNPs analyzed, rs303056 (C), rs3798691 (C), rs533558 (G) showed allelic association with spina bifida risk in Hispanics. Genotypic association analysis showed that rs3798691 was associated with spina bifida risk under a dominant model in Hispanics (OR = 1.78, 95% CI: 1.13\~2.87). SNP rs533558 also showed an association under a dominant model, but only in native-born Hispanics (OR = 3.32, 95%CI: 1.08\~10.18). Subsequent haplotype analysis predicted two haplotype blocks in Hispanics. Haplotype AGCGC of block1 (rs537112- rs533558-rs303050-rs3798694-rs3798691) had an average frequency of 0.133 and was associated with an increased risk, OR = 1.73 (1.08-2.77) compared to all other haplotypes. Since no high risk SNP has been discovered, these high risk blocks will be thoroughly sequenced to search for other variants (Table [5](#T5){ref-type="table"}).

CREBBP
------

Among the 8 SNPs analyzed, the heterozygous status of SNP rs129986 (TC) was associated with a reduced risk in all subjects (OR = 0.27, 95% CI: 0.11\~0.69). The homozygous status of the minor allele, CC, was not observed. The TC genotype was observed in only 6 cases and they were all Hispanics.

CARM1
-----

6 SNPs were genotyped. In Whites, the minor allele (C) of rs17616105 showed a reduced risk with OR = 0.41 (95%CI: 0.22\~0.75). Genotype analysis showed that this effect followed a dominant inheritance model (OR~CC+CT~= 0.40, 95% CI: 0.20\~0.40), and was not observed in the Hispanics.

ALX1
----

3 SNPs were genotyped. No association was observed between any SNP and spina bifida risk. It is known that the *Cart1*knockout mouse responses to maternal supplementation with folic acid \[[@B23]\]. The majority of the DNA samples for this study were collected after folic acid fortification is implied in the USA, which might interact with the genotyping effect; however, our study lacks the statistic power to analyze the gene-environment interaction.

To our knowledge, this is the first study evaluating human *CREBBP*, *EP300*, *CARM1*, *TFAP2A*, and *ALX1*genes as possible risk factors for spina bifida. Association between *CITED2*and spina bifida has been studied before, and results from our current study are consistent with the previous findings \[[@B14]\]. Modest associations were observed between spina bifida risk and *TFAP2A, EP300, CITED2, CREBBP1*and *CARM1*. No association was observed in *ALX1*gene. However, given the number of comparisons made, relatively few associations emerged. Although NTDs are multifactorial diseases, it cannot be excluded that the studied genes may contain rare mutations that cause some of the NTDs. With the most advanced next-generation sequencing technique being available, we may be able to discover such rare variants in our study population.

The strengths of this study include its population-based ascertainment of cases and controls and its evaluation of race/ethnicity as potential modifiers of risk in the presence of variant genotypes and haplotypes. A major limitation of our study was the small sample size, which reduced the statistical power of analyses. Replication of some of the modest findings in a larger sample set may be warranted.

Conclusions
===========

We have observed modest associations with risk of spina bifida in *CITED2*, *EP300*, *CREBBP*, *TFAP2A*and *CARM1*genes but not *ALX1*gene. These modest associations were not statistically significant after correction for multiple comparisons. Future effort will focus on searching for potential functional variants and rare causal mutations in these potential candidate genes.
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**CREB**: cAMP response element binding protein; **CRE**: cyclic AMP-responsive; ***CITED2***: Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2; ***EP300***: E1A binding protein p300 (Alias: p300); ***CREBBP***: CREB binding protein (Alias: CBP); ***TFAP2A***: transcription factor AP-2 alpha (activating enhancer binding protein 2 alpha) (Alias: AP-2); ***CARM1***: coactivator-associated arginine methyltransferase 1; ***ALX1***: ALX homeobox 1 (Alias: CART1).
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